Endoscopic diagnosis and management of peptic ulcer bleeding: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Update 2026.

Key Takeaways for GI Nurses

• Capsule-based technologies (video capsule endoscopy and telemetric blood-sensing capsules) are not recommended for routine triage of suspected upper GI hemorrhage — nurses should not expect these tools to replace standard pre-endoscopy assessment protocols.
• If IV erythromycin is not stocked or unavailable, IV metoclopramide may be used as a prokinetic alternative in select patients with severe or ongoing active bleeding to improve mucosal visualization prior to scope insertion — nurses should be familiar with dosing, administration timing, and monitoring for both agents.
• High-dose IV PPI therapy pre-endoscopy is still supported, but the guideline is explicit that PPI initiation should never delay timely endoscopy — this reinforces the importance of coordinated, efficient triage between medical and nursing teams.
• The guideline moves away from mandating emergent (≤6h) or urgent (≤12h) scoping for all UGIH patients, reserving this urgency specifically for hemodynamically unstable patients despite resuscitation — this has direct implications for staffing, on-call scheduling, and prioritization within endoscopy units.

Clinical Relevance

This 2026 update to the ESGE guideline reflects a more nuanced, patient-tailored approach to acute upper GI hemorrhage management, with meaningful implications for endoscopy nursing workflows. The shift away from routine emergent/urgent endoscopy timing (unless hemodynamic instability persists despite resuscitation) means nursing teams may see fewer overnight or middle-of-the-night procedure calls for stable bleeding patients, allowing for better-resourced daytime procedures with full staffing and equipment availability. This has downstream benefits for patient safety, as procedures performed during regular hours often benefit from more experienced staffing ratios and reduced fatigue-related risk.

The pharmacologic recommendations also matter operationally. Nurses administering pre-procedure medications need to understand not just erythromycin's established role as a prokinetic to clear gastric contents and blood, but now also metoclopramide as a viable backup when erythromycin is unavailable — including differences in onset, cardiac monitoring considerations (notably QT prolongation risk with erythromycin), and potential extrapyramidal side effects with metoclopramide. Similarly, reinforcing that high-dose IV PPI infusion should never delay endoscopy requires close communication between bedside nursing, pharmacy, and the endoscopy team to avoid treatment bottlenecks — a workflow issue that nursing leadership should proactively address in unit protocols and order sets.

Finally, the update on Forrest IIb adherent clot management — recommending endoscopic clot removal with hemostasis therapy — underscores the continued need for nurses to be well-versed in assisting with mechanical clot debridement techniques and hemostatic modalities (thermal, mechanical, injection) during the procedure itself. This reinforces the value of ongoing competency training in endoscopic hemostasis assistance, instrument handling, and rapid equipment turnover, particularly for units managing high volumes of GI bleed cases.

Bottom Line

For busy GI nurses, the core message of this update is that speed for speed's sake is no longer the default in UGIH management — early endoscopy remains important, but true emergent scoping should be reserved for hemodynamically unstable patients, while pharmacologic optimization (PPI, prokinetics) and thorough hemostatic technique take precedence over rigid timing mandates, reshaping both triage decisions and endoscopy suite scheduling priorities.